10-Q: Hypha Labs Reports Q1 2025 Results, Focuses on Bioreactor Development

Hypha Labs, formerly Digipath, reports its Q1 2025 results, highlighting its transition to bioreactor development and commercialization after selling its cannabis testing lab.

Summary

• Hypha Labs, Inc., formerly Digipath, reports financial results for the three months ended December 31, 2024.
• The company completed the sale of its cannabis testing lab, Digipath Labs, on February 20, 2024, and is now focused on developing and commercializing a bioreactor for producing nutritionally beneficial mushrooms.
• For the three months ended December 31, 2024, Hypha Labs reported no revenues from continuing operations.
• General and administrative expenses were $1,025,111, primarily due to increased corporate overhead and the issuance of Series C Preferred shares to the sole officer.
• Professional fees totaled $280,153, including $67,000 in non-cash, stock-based compensation.
• The company reported a net loss from continuing operations of $1,339,641, or $(0.01) per share.
• As of December 31, 2024, Hypha Labs had cash on hand of $36,583, negative working capital of $1,294,879, and an accumulated deficit of $21,887,067, raising substantial doubt about its ability to continue as a going concern.
• The company intends to continue the design, development and testing of the Hypha Micropearl bioreactor over the next nine months.
• Hypha Labs aims to market the Hypha Micropearl bioreactor by the end of calendar year 2025.
• Subsequent to the quarter, the company extended the maturity dates of several notes payable to July 31, 2025, in exchange for deferred payments.

Sentiment

Score: 3

Explanation: The sentiment is low due to the lack of revenue, significant net loss, and concerns about the company's ability to continue as a going concern. However, the company's strategic shift and development of an innovative product offer some potential for future improvement.

Positives

• The company has completed the sale of its cannabis testing business, allowing it to focus on a new venture.
• Hypha Labs is developing an innovative bioreactor technology for home production of functional mushrooms.
• The company is actively working on the design, development, and testing of the Hypha Micropearl bioreactor.
• The company is targeting a market launch of the Hypha Micropearl bioreactor by the end of 2025.

Negatives

• The company reported no revenues from continuing operations for the three months ended December 31, 2024.
• General and administrative expenses increased significantly, impacting profitability.
• The company reported a substantial net loss from continuing operations.
• Hypha Labs has a limited cash balance and negative working capital, raising concerns about its ability to continue as a going concern.
• The company is dependent on raising additional capital to fund its operations and the development of its bioreactor.

Risks

• The company's ability to continue as a going concern is uncertain due to limited cash and negative working capital.
• The success of the Hypha Micropearl bioreactor is dependent on successful design, development, testing, and manufacturing.
• The company faces the risk of not being able to raise sufficient capital to fund its operations and the development of its bioreactor.
• The company's ability to achieve its targeted market launch date of the Hypha Micropearl bioreactor by the end of 2025 is uncertain.
• The company is subject to risks associated with entering into a manufacturing arrangement outside the United States.

Future Outlook

Hypha Labs intends to continue the design, development, and testing of the Hypha Micropearl bioreactor over the next nine months, with a goal to market the product by the end of calendar year 2025.

Management Comments

• The company intends to raise funds to complete the development and testing of its bioreactor over the next 6 to 12 months and to fund the initial launch of commercial sales of its bioreactor device.
• The Company is also currently evaluating future investments into potential acquisition targets.

Industry Context

Hypha Labs' transition from cannabis testing to bioreactor development reflects a strategic shift to capitalize on the growing market for functional foods and home-based biotechnology solutions.

Comparison to Industry Standards

• It is difficult to compare Hypha Labs' current financial performance to industry standards due to its recent strategic shift and lack of revenue from continuing operations.
• Companies in the functional food and home appliance sectors, such as Keurig Dr Pepper (KDP) or Instant Brands, may serve as aspirational benchmarks for future performance, but are not directly comparable at this stage.
• The success of the Hypha Micropearl bioreactor will depend on its ability to compete with existing mushroom cultivation methods and other home-based food production systems.

Related Party Transactions

• During the three months ended December 31, 2024 the Company incurred compensation expense of 30,000 for services provided by its sole officer.
• During the three months ended December 31, 2024 the Company accrued fees of $ 5,000 for services provided by its directors.
• On December 10, 2024, the Company entered into a Securities Purchase Agreement with A. Stone Douglass, the Companys Chairman, President, Chief Executive Officer, Chief Financial Officer, Secretary and Director, pursuant to which Mr. Douglass purchased 1,000 shares of the Companys Series C Preferred stock for a purchase price of $ 100 .

Stakeholder Impact

• Shareholders face significant risk due to the company's financial condition and dependence on raising additional capital.
• Employees are impacted by the company's strategic shift and potential need for cost-cutting measures.
• Customers may benefit from the development of the Hypha Micropearl bioreactor, providing a new option for home-based mushroom production.
• Suppliers and creditors face increased risk due to the company's financial instability.

Next Steps

• Continue the design, development, and testing of the Hypha Micropearl bioreactor.
• Seek to enter into a manufacturing arrangement outside the United States.
• Raise funds to complete the development and testing of the bioreactor and fund the initial launch of commercial sales.
• Evaluate future investments into potential acquisition targets.

Key Dates